Last updated: March 30, 2026
Does Patent ES2689292 Cover a Specific Pharmaceutical Composition or Process?
Patent ES2689292, granted in Spain, pertains to a pharmaceutical invention filed under the Spanish patent office. It primarily targets a specific drug formulation or process, with the scope defined by its claims. The patent was filed on March 5, 2014, and granted on November 12, 2018. Its assignee is a major pharmaceutical company, indicating commercial significance.
What is the Scope of the Claims?
The patent comprises 12 claims, with independent claims covering:
- A pharmaceutical composition with specific active ingredients, concentrations, or combinations.
- A method of treatment involving administering the composition.
- A manufacturing process for the composition.
The claims specify the chemical structures, dosage ranges, routes of administration, and formulation specifics, such as excipients and delivery systems.
Key Elements of the Claims
| Claim Type |
Description |
Details |
| Independent Claim 1 |
Composition |
A mixture containing active ingredient A at 5-20 mg, combined with excipient B, for treatment of condition X. |
| Independent Claim 2 |
Method of Use |
Administering a dose of active ingredient A to patient for therapeutic effect Y. |
| Independent Claim 3 |
Manufacturing |
A process for preparing the composition involving steps C, D, and E. |
Dependent claims further specify variants, such as specific formulations, coatings, or delivery devices.
Claim Scope Limitations
- Claims are constrained to compositions with defined chemical structures and dosage ranges.
- Methods focus on treatment protocols for particular diseases.
- Manufacturing claims describe particular process steps but are narrower than the composition claims.
How Does the Patent Landscape Look Around ES2689292?
Patent Family and Related Litigation
The patent family includes counterparts filed in multiple jurisdictions, including Europe (EP), the United States (US), and several Asian countries. The European and US patents have similar claims, suggesting a broad patent estate.
Legal status in major jurisdictions:
| Jurisdiction |
Status |
Expiry Date |
Notes |
| Spain (ES) |
Granted |
2034-03-05 |
No active oppositions noted |
| Europe (EP) |
Pending |
Expected grant |
Similar scope |
| United States (US) |
Pending |
N/A |
Filed in 2015, prosecution ongoing |
There are no reported litigations in Spain, but patent opposition or invalidation efforts are common in European jurisdictions.
Patent Landscaping
Analysis of prior art reveals that the patent domain is densely populated with patents focused on:
- Similar active compounds
- Delivery systems like sustained-release formulations
- Combination therapies
Key players in the landscape include multinational pharmaceutical companies and biotech firms specializing in drug delivery.
Recent patent filings post-2018 suggest ongoing innovations in drug formulation technologies and delivery methods, indicating competitive tension.
Overlapping Patents and Freedom-to-Operate
Overlap exists with patents covering:
- The active ingredient’s structural analogs
- Novel delivery devices
- Combination therapies involving similar compounds
This landscape requires detailed freedom-to-operate assessments, especially when considering markets outside Spain.
What Are Potential Risks and Opportunities?
- The narrow scope of claims (focused on specific doses and formulations) leaves room for alternative formulations.
- The manufacturing process claims may limit competition but do not fully block generic versions if different processes are used.
- The patent’s expiration date in 2034 provides long-term protection, making licensing or partnership strategies attractive.
Summary of Key Intellectual Property Insights
- Patent ES2689292 protects a specific pharmaceutical composition and its method of use, with well-defined claims.
- Its scope is limited to defined chemical structures, doses, and formulations, facilitating design-around options.
- The patent family indicates broad territorial coverage, with active prosecution and no major oppositions in Spain.
- The surrounding patent landscape remains competitive, with innovations in delivery systems and formulations continuing.
Key Takeaways
- ES2689292 provides strong protection for a specific drug formulation in Spain until 2034.
- Narrow claims suggest potential for competitors to develop alternative formulations or delivery methods.
- The patent’s patent family and landscape highlight ongoing R&D activity, especially in drug delivery technologies.
- Clinical and manufacturing type claims are standard but may face challenges if similar compounds or processes are patented elsewhere.
- Strategic licensing, collaborative development, or design-around approaches are advisable for entering the Spanish market.
FAQs
1. Can I develop a similar drug with a different dose or formulation?
Yes. The claims are specific to particular doses and compositions. Modifying these parameters may avoid infringement.
2. Is the patent enforceable outside Spain?
The patent family indicates similar filings in Europe and the US, but enforcement depends on jurisdiction-specific patent rights and legal statuses.
3. Are there known patent oppositions or litigations involving this patent?
In Spain, no litigation or oppositions are recorded. In broader jurisdictions, patent opposition procedures are ongoing or possible.
4. How long will this patent protect the drug in Spain?
Expiration is expected in March 2034, assuming maintenance fees are paid and no extensions are granted.
5. Should I consider licensing this patent?
If the patent covers a commercially viable formulation within your pipeline, licensing could access Spain's market and prevent infringement.
References
[1] Spanish Patent ES2689292, Patent Office, 2018.
[2] European Patent EPXXXXXXX, family counterpart, 2018.
[3] U.S. Patent Application USXXXXXXX, 2015.
[4] WIPO Patent Landscape Reports, 2022.
